Van Lent Eric R 4/A
4/A · 180 Life Sciences Corp. · Filed Jun 30, 2025
Insider Transaction Report
Form 4/AAmended
Van Lent Eric R
Chief Accounting Officer
Transactions
- Award
Common Stock
2025-06-17+8,174→ 8,174 total - Award
Non-Qualified Stock Option (right to buy)
2025-06-17+25,000→ 25,000 totalExercise: $0.93Exp: 2035-06-17→ Common Stock (25,000 underlying)
Footnotes (3)
- [F1]Represents restricted stock shares subject to time-based vesting, which vest at the rate of 1/2 of such shares on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2022 Equity Compensation Plan (the "Equity Plan").
- [F2]Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as Chief Accounting Officer of the Issuer.
- [F3]The options vest 1/2 on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2025 Option Incentive Plan. The 2025 Option Incentive Plan is subject to stockholder approval and (i) no options can be exercised prior to obtaining stockholder approval for such plan, and (ii) the outstanding options will be cancelled, if stockholder approval is not obtained.